The Definitive Peptide Research Reference Guide — Compound Review

✦Use code HEALTH for 15% off at Purgo Labs✦
Audience Hub5 Compounds Reviewed

Peptides for Weight Loss

The landscape of research peptides for weight loss is dominated by GLP-1 receptor agonists — semaglutide, tirzepatide, and retatrutide — which have produced the most significant pharmacological weight loss ever documented in clinical trials. This hub covers all five evidence-supported compounds, their mechanisms, clinical trial data, and compound-specific dosing guides.

View All CompoundsClinical Trial Data
24.2%
Peak weight loss (retatrutide Phase 2)
Highest ever documented
22.5%
Tirzepatide SURMOUNT-1
72-week trial, n=2,539
14.9%
Semaglutide STEP-1
68-week trial, n=1,961
5
Evidence-supported compounds
GLP-1s, AOD-9604, GHK-Cu

How Weight Loss Peptides Work

Appetite Suppression
GLP-1 receptor agonists act on hypothalamic GLP-1 receptors to reduce food reward signaling and increase satiety. STEP-1 participants reported 40% reduction in hunger scores vs placebo.
Energy Expenditure
Retatrutide's glucagon receptor agonism increases hepatic fat oxidation and resting energy expenditure by 15–20% above baseline — a mechanism absent in semaglutide monotherapy.
Direct Lipolysis
AOD-9604 stimulates lipolysis through a non-GH receptor pathway, directly increasing fat cell breakdown without the anabolic or diabetogenic effects of full-length GH.
Insulin Sensitization
GIP receptor agonism (tirzepatide, retatrutide) improves adipocyte insulin sensitivity, reducing ectopic fat deposition and improving the metabolic environment for weight loss.

Weight Loss Peptides: Compound-Specific Guides

Each compound has a dedicated dosing guide with titration schedules, side effect management, and protocol recommendations.

SemaglutideGLP-1 RAPhase 3 (STEP 1–5, SELECT)
GLP-1R agonist → ↓ appetite, ↓ gastric emptying, ↑ satiety

GLP-1 receptor agonist. STEP-1 trial: 14.9% body weight reduction at 68 weeks. Gold standard for GLP-1 monotherapy.

Standard dose:0.25mg → 2.4mg/week (20-week titration)
Weight Loss Guide Full Dosage Guide
TirzepatideGIP/GLP-1 RAPhase 3 (SURMOUNT 1–4, SURPASS-CVOT)
GIP + GLP-1R dual agonist → ↑ lipolysis, ↓ appetite, ↑ insulin sensitivity

Dual GIP + GLP-1 receptor agonist. SURMOUNT-1: up to 22.5% body weight reduction at 72 weeks — superior to semaglutide.

Standard dose:2.5mg → 15mg/week (20-week titration)
Weight Loss Guide Full Dosage Guide
RetatrutideTriple AgonistPhase 2 (Jastreboff et al., NEJM 2023)
GIP + GLP-1 + GCGR triple agonist → ↑ energy expenditure, ↑ lipolysis, ↓ appetite

Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 trial: up to 24.2% body weight reduction at 48 weeks — highest efficacy reported.

Standard dose:2mg → 12mg/week (Phase 2 protocol)
Weight Loss Guide Full Dosage Guide
AOD-9604GH FragmentPhase 2 (Heffernan et al.)
Non-GHR lipolytic pathway → ↑ fat oxidation, ↓ lipogenesis

hGH176-191 fragment. Stimulates lipolysis and inhibits lipogenesis without GH receptor binding. No effect on IGF-1 or blood glucose.

Standard dose:250–500mcg/day, AM fasted
Weight Loss Guide Full Dosage Guide
GHK-CuCopper PeptidePreclinical + Phase 1
SPARC upregulation → ↑ adiponectin, ↓ lipogenic gene expression

Copper-binding tripeptide with metabolic and tissue-remodeling effects. Supports skin elasticity during weight loss and modulates fat metabolism genes.

Standard dose:2–5mg/day injectable or topical
Weight Loss Guide Full Dosage Guide

Clinical Trial Weight Loss Data

Randomized controlled trial data for weight loss peptides. All figures represent mean percentage body weight reduction from baseline.

CompoundTrialnDurationWeight LossPlacebo
Semaglutide 2.4mgSTEP-11,96168 wks14.9%2.4%
Semaglutide 2.4mgSTEP-21,21068 wks9.6%3.4%
Semaglutide 2.4mgSTEP-361168 wks16.0%5.7%
Tirzepatide 15mgSURMOUNT-12,53972 wks22.5%2.4%
Tirzepatide 15mgSURMOUNT-293872 wks15.7%3.3%
Retatrutide 12mgPhase 233848 wks24.2%2.1%
AOD-9604 1mgPhase 230012 wks~2–3%~0.5%

Choosing the Right Weight Loss Peptide

ProfileBest ChoiceRationale
Maximum weight loss efficacyRetatrutide 12mgHighest documented weight loss (24.2%) via triple receptor agonism
Obesity + Type 2 DiabetesTirzepatide 15mgDual GIP/GLP-1 agonism improves both weight and glycemic control; FDA-approved for T2D
First-line GLP-1 therapySemaglutide 2.4mgLongest safety record, FDA-approved (Wegovy), extensive cardiovascular data (SELECT trial)
Fat loss without appetite suppressionAOD-9604 500mcg/dayDirect lipolysis without GLP-1 CNS effects; suitable for those who cannot tolerate GLP-1 nausea
Skin support during weight lossGHK-Cu 2–5mg/dayCollagen remodeling and skin elasticity support during rapid weight loss phases
Comprehensive stackGLP-1 + AOD-9604 + GHK-CuGLP-1 for appetite/metabolic control + AOD-9604 for direct lipolysis + GHK-Cu for skin integrity

Compound-Specific Weight Loss Guides

Each compound has a dedicated weight loss guide with full titration schedules, side effect management, and protocol recommendations.

Semaglutide for Weight Loss
STEP trial data, 5-phase titration, plateau management
Tirzepatide for Weight Loss
SURMOUNT data, dual mechanism, vs semaglutide comparison
AOD-9604 for Weight Loss
GH fragment mechanism, dosing protocol, stacking guide
GHK-Cu for Weight Loss
Metabolic effects, skin support during weight loss, protocol
Retatrutide Dosage Guide
Triple agonist protocol, Phase 2 titration, vs tirzepatide
GLP-1 Peptides for Weight Loss
Comprehensive GLP-1 comparison guide

Frequently Asked Questions

What are the best peptides for weight loss?
The most evidence-supported peptides for weight loss are the GLP-1 receptor agonists: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide. In clinical trials, semaglutide produced 14.9% body weight reduction (STEP-1), tirzepatide up to 22.5% (SURMOUNT-1), and retatrutide up to 24.2% (Phase 2). For non-GLP-1 options, AOD-9604 (a GH fragment) and GHK-Cu (a copper peptide) show supporting metabolic effects in preclinical research.
How do GLP-1 peptides cause weight loss?
GLP-1 receptor agonists work through multiple complementary mechanisms: (1) slowing gastric emptying, which prolongs satiety after meals; (2) acting on hypothalamic GLP-1 receptors to reduce appetite and food reward signaling; (3) increasing insulin secretion in a glucose-dependent manner; and (4) reducing glucagon secretion. Tirzepatide adds GIP receptor agonism, which enhances adipocyte lipolysis and improves insulin sensitivity. Retatrutide adds glucagon receptor agonism, which increases energy expenditure and hepatic fat oxidation.
What is AOD-9604 and how does it help with weight loss?
AOD-9604 is a synthetic fragment of human growth hormone (hGH176-191) that retains the lipolytic properties of GH without the anabolic or diabetogenic effects. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) through a non-GH receptor pathway. In Phase 2 clinical trials, AOD-9604 at 1mg/day produced modest but statistically significant fat loss over 12 weeks. It does not affect blood glucose or IGF-1 levels, making it a metabolically neutral fat-loss tool.
Can you combine peptides for weight loss?
The most researched combination is a GLP-1 agonist (semaglutide or tirzepatide) as the primary agent, with AOD-9604 added for its direct lipolytic effect. GHK-Cu may be added to support skin elasticity during rapid weight loss. BPC-157 is sometimes included to support gut motility and reduce GI side effects from GLP-1 therapy. These combinations are research-only and have not been studied in formal clinical trials as stacks.
How long does it take for weight loss peptides to work?
GLP-1 agonists show measurable weight loss within 4–8 weeks of reaching therapeutic dose, with maximum effect at 52–68 weeks. Semaglutide titration takes 16–20 weeks to reach the 2.4mg/week maintenance dose. Tirzepatide titration takes 20 weeks to reach the 15mg/week maintenance dose. AOD-9604 shows effects within 12 weeks at therapeutic dose. Weight loss plateaus are common at 52–68 weeks and require dose optimization or adjunct strategies.
What are the side effects of weight loss peptides?
GLP-1 agonists: nausea (44%), vomiting (24%), diarrhea (30%), and constipation (24%) are most common, especially during titration. These are dose-dependent and typically improve after 4–8 weeks. Rare but serious: pancreatitis, gallbladder disease, and potential thyroid C-cell effects (seen in rodents, not confirmed in humans). AOD-9604: generally well-tolerated; mild injection site reactions are the primary adverse effect. GHK-Cu: topical use is very well-tolerated; injectable research is limited.
Are weight loss peptides safe for long-term use?
Semaglutide and tirzepatide have the most long-term safety data: STEP and SURMOUNT trials ran 68–104 weeks with acceptable safety profiles. The SELECT trial (semaglutide, 17,604 patients, 33 months) demonstrated cardiovascular risk reduction in patients with obesity and established CVD. AOD-9604 and GHK-Cu have limited long-term human data. All weight loss peptides should be used under medical supervision with regular monitoring of metabolic markers.
Do you regain weight after stopping weight loss peptides?
Yes — weight regain is well-documented after discontinuing GLP-1 agonists. The STEP-4 withdrawal trial showed that patients who stopped semaglutide regained approximately two-thirds of their lost weight within 52 weeks. This reflects the underlying biology: GLP-1 therapy suppresses appetite hormonally, and when the drug is removed, appetite returns. Long-term maintenance therapy or transition to lifestyle interventions is required to sustain weight loss.

Research purposes only. All compounds discussed on this page are research chemicals. Semaglutide and tirzepatide are FDA-approved medications when prescribed by a licensed physician; all other compounds are research-only. This content is not medical advice. Consult a qualified healthcare provider before beginning any weight loss protocol.

Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.